Purpose <p>Psoriasis is a chronic immune-mediated skin disorder characterized by inflammation, keratinocyte hyperproliferation, and scaly plaques. Conventional therapies, including topical agents, systemic immunosuppressants, and biologics, are limited by poor skin penetration, systemic toxicity, high cost, and poor patient compliance. This study aims to explore minimally invasive transdermal drug delivery systems (MIDDS) as an emerging approach to enhance localized, controlled, and sustained drug delivery for effective management of psoriasis.</p> Method <p>A comprehensive review of recent literature and patents was conducted, focusing on MIDDS technologies that overcome the stratum corneum barrier. Emphasis was placed on microneedles, iontophoresis, sonophoresis, electroporation, and nanoparticle-based systems. Innovations such as dual-drug delivery, biodegradable polymers, and biosensor integration were analysed for their therapeutic effects.</p> Results <p>Microneedles, particularly dissolving and hollow types, demonstrated significant promise in delivering small molecules and biologics directly into the psoriatic area with improved efficacy and safety. Nanocarriers, including gold and silver nanoparticles, provided enhanced drug stability, controlled release, and synergistic anti-inflammatory activity. Iontophoresis and sonophoresis further improved transdermal penetration through controlled physical stimulation. Emerging designs utilizing multi-layered microneedles and biodegradable materials showed improved patient compliance and reduced systemic exposure.</p> Conclusion <p>MIDDS represents a transformative and patient-centered approach for psoriasis therapy. By offering targeted and sustained delivery with minimal invasiveness, these systems can enhance therapeutic outcomes and improve the quality of treatments. Future integration with nanotechnology and biosensors may enable personalized treatment and real-time disease monitoring.</p> Graphical Abstract <p></p>